Current Evidence and Future Directions of PCSK9 Inhibition
Recent scientific and therapeutic advances in proprotein convertase subtilisin kexin type 9 (PCSK9) inhibition have opened a chapter in the management of hypercholesterolemia, especially in patients who are inadequately controlled on or intolerant to statins. The two PCSK9 monoclonal antibodies, evo...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Radcliffe Medical Media
2021-02-01
|
| Series: | US Cardiology Review |
| Online Access: | https://www.uscjournal.com/articleindex/usc.2020.17 |